Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22475351 | 0.96 | AR (0.39) | ARMTNR1AMTNR1BCYP2D6POLB | |
| SCHEMBL22475354 | 0.93 | AR (0.38) | ARMTNR1AMTNR1BCYP2D6POLB | |
| SCHEMBL22475348 | 0.92 | AR (0.36) | ARMTNR1AMTNR1BCYP2D6POLB | |
| SCHEMBL22417598 | 0.92 | AR (0.36) | ARMTNR1AMTNR1BCYP2D6POLB | |
| SCHEMBL21162913 | 0.92 | AR (0.36) | ARMTNR1AMTNR1BCYP2D6POLB | |
| SCHEMBL11920351 | 0.87 | MTNR1A (0.36) | MTNR1AMTNR1BPOLBAPEX1HTT | |
| SCHEMBL11920352 | 0.85 | TSHR (0.44) | PRKCATHRB | |
| SCHEMBL6880397 | 0.85 | MTNR1A (0.46) | ARMTNR1AMTNR1BPOLBMAPT | |
| SCHEMBL11920350 | 0.84 | CYP2D6 (0.46) | CYP2D6POLBMAPTLMNAMEN1 | |
| SCHEMBL21163118 | 0.84 | MTNR1A (0.34) | MTNR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675422-B1 | DENTAL COMPOSITIONS COMPRISING ETHYLENICALLY UNSATURATED ADDITION-FRAGMENTATION AGENT | 3M INNOVATIVE PROPERTIES CO (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2965742-B1 | DENTAL COMPOSITIONS COMPRISING ETHYLENICALLY UNSATURATED ADDITION-FRAGMENTATION AGENT | 3M INNOVATIVE PROPERTIES CO (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-2675783-B1 | ADDITION-FRAGMENTATION AGENTS | 3M INNOVATIVE PROPERTIES CO (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10370322-B2 | Addition-fragmentation agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3502092-A1 | ADDITION-FRAGMENTATION AGENTS | 3M Innovative Properties Company (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20170210693-A1 | ADDITION-FRAGMENTATION AGENTS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170210693-A1 | ADDITION-FRAGMENTATION AGENTS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-9403966-B2 | Addition-fragmentation agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403966-B2 | Addition-fragmentation agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9320685-B2 | Dental compositions comprising ethylenically unsaturated addition-fragmentation agent | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320685-B2 | Dental compositions comprising ethylenically unsaturated addition-fragmentation agent | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150238389-A1 | DENTAL COMPOSITIONS COMPRISING ETHYLENICALLY UNSATURATED ADDITION-FRAGMENTATION AGENT | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150238389-A1 | DENTAL COMPOSITIONS COMPRISING ETHYLENICALLY UNSATURATED ADDITION-FRAGMENTATION AGENT | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150203658-A1 | ADDITION-FRAGMENTATION AGENTS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-07-23 | — | — | US | disclosed |
| US-20150203658-A1 | ADDITION-FRAGMENTATION AGENTS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-07-23 | — | — | US | disclosed |
| US-9056043-B2 | Dental compositions comprising ethylenically unsaturated addition-fragmentation agent | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056043-B2 | Dental compositions comprising ethylenically unsaturated addition-fragmentation agent | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2012112304-A1 | ADDITION-FRAGMENTATION AGENTS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120208965-A1 | ADDITION-FRAGMENTATION AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-08-16 | — | — | US | disclosed |
| US-20120208965-A1 | ADDITION-FRAGMENTATION AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370322-B2 | Addition-fragmentation agents | NR4A1, PARP14, MTX1 | AR 578/4885MTNR1A 77/4885MTNR1B 83/4885 |
| US-20120208965-A1 | ADDITION-FRAGMENTATION AGENTS | NR4A1, PARP14, MTX1 | AR 578/4885MTNR1A 77/4885MTNR1B 83/4885 |
| US-20170210693-A1 | ADDITION-FRAGMENTATION AGENTS | NR4A1, PARP14, MTX1 | AR 578/4885MTNR1A 77/4885MTNR1B 83/4885 |
| US-20150238389-A1 | DENTAL COMPOSITIONS COMPRISING ETHYLENICALLY UNSATURATED ADDITION-FRAGMENTATION AGENT | NR4A1, RXRG, RXRA | AR 1478/4885MTNR1A 467/4885MTNR1B 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.